Download PDF
Semin Liver Dis 2006; 26(2): 142-152
DOI: 10.1055/s-2006-939752
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Hepatitis B Virus-Related Cirrhosis: Natural History and Treatment

Chia-Ming Chu1 , Yun-Fan Liaw1
  • 1Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan
Further Information

Publication History

Publication Date:
03 May 2006 (online)

    Permissions and Reprints

ABSTRACT

In patients with compensated hepatitis B virus (HBV) cirrhosis, active viral replication correlates significantly with the risk of hepatic flare, decompensation, and the development of hepatocellular carcinoma (HCC). The 5-year survival of patients with compensated cirrhosis was reported to be 80 to 85%, and is significantly lower in patients with replicative HBV. Both interferon and maintenance lamivudine therapy have been shown to reduce the risk of decompensation or HCC and prolong survival in responders. A finite course of interferon is recommended as the first-line agent. For patients who had a contraindication for or who have failed interferon therapy, direct antiviral(s) can be considered for long-term treatment. Once decompensation occurs, mortality increases remarkably. Early treatment with nucleoside analogues should be instituted. Lamivudine therapy is associated with rapid viral suppression, improvement in Child-Pugh scores, and improved survival, but drug resistance is a major problem and is associated directly with a poor clinical outcome. Adefovir or entecavir is preferred in patients with decompensated cirrhosis who require long duration of treatment, due to the lower rate of development of resistance.

KEYWORDS

Cirrhosis - decompensation - nucleos(t)ide analogue - hepatocellular carcinoma - interferon

REFERENCES

  • 1 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Hepatology. 1988;  8 493-496
    PubMedGoogle Scholar
  • 2 Fattovich G, Brollo L, Giustina G et al.. Natural history and prognostic factors for chronic hepatitis type B.  Gut. 1991;  32 294-298
    PubMedGoogle Scholar
  • 3 Sumi H, Yokosuka O, Seki N et al.. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.  Hepatology. 2003;  37 19-26
    CrossrefPubMedGoogle Scholar
  • 4 Liaw Y F, Chen Y C, Sheen I S et al.. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.  Gastroenterology. 2004;  126 1024-1029
    CrossrefPubMedGoogle Scholar
  • 5 Liaw Y F, Lin D Y, Chen T J, Chu C M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Liver. 1989;  9 235-241
    PubMedGoogle Scholar
  • 6 Tsai S L, Yang P M, Lai M Y et al.. Natural history of hepatitis B surface antigen-positive cirrhosis in Taiwan: a clinicopathological study.  J Gastroenterol Hepatol. 1988;  3 583-592
    PubMedGoogle Scholar
  • 7 Realdi G, Fattovich G, Hadziyannis S et al.. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).  J Hepatol. 1994;  21 656-666
    CrossrefPubMedGoogle Scholar
  • 8 de Jongh F E, Janssen H L, de Man R A et al.. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver.  Gastroenterology. 1992;  103 1630-1635
    PubMedGoogle Scholar
  • 9 Chu C M, Liaw Y F, Sheen I S, Lin D Y, Huang M J. Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody.  Hepatology. 1983;  3 947-950
    PubMedGoogle Scholar
  • 10 Chu C M, Hung S J, Lin J, Tai D I, Liaw Y F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels.  Am J Med. 2004;  116 829-834
    CrossrefPubMedGoogle Scholar
  • 11 Liaw Y F, Chen J J, Chen T J. Acute exacerbation in patients with liver cirrhosis: a clinicopathological study.  Liver. 1990;  10 177-184
    PubMedGoogle Scholar
  • 12 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP).  Hepatology. 1997;  26 1338-1342
    CrossrefPubMedGoogle Scholar
  • 13 Liaw Y F, Pao C C, Chu C M, Sheen I S, Huang M J. Changes of serum HBV-DNA in two types of clinical events preceding spontaneous HBeAg seroconversion in chronic type B hepatitis.  Hepatology. 1987;  7 1-3
    PubMedGoogle Scholar
  • 14 Liaw Y F, Sheen I S, Chen T J, Chu C M, Pao C C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study.  Hepatology. 1991;  13 627-631
    CrossrefPubMedGoogle Scholar
  • 15 Chung H T, Lai C L, Lok A S. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis.  Hepatology. 1995;  22 25-29
    CrossrefPubMedGoogle Scholar
  • 16 Fattovich G, Giustina G, Schalm S W et al.. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis.  Hepatology. 1995;  21 77-82
    CrossrefPubMedGoogle Scholar
  • 17 Fattovich G, Pantalena M, Zagni I et al.. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.  Am J Gastroenterol. 2002;  97 2886-2895
    CrossrefPubMedGoogle Scholar
  • 18 Liaw Y F, Sung J J, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
    CrossrefPubMedGoogle Scholar
  • 19 Chen Y C, Sheen I S, Chu C M, Liaw Y F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.  Gastroenterology. 2002;  123 1084-1089
    CrossrefPubMedGoogle Scholar
  • 20 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.  Gastroenterology. 2004;  127(5 suppl 1) S35-S50
    CrossrefPubMedGoogle Scholar
  • 21 Kato Y, Nakata K, Omagari K et al.. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses.  Cancer. 1994;  74 2234-2238
    PubMedGoogle Scholar
  • 22 Ikeda K, Saitoh S, Suzuki Y et al.. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study.  Cancer. 1998;  82 827-835
    CrossrefPubMedGoogle Scholar
  • 23 Chiaramonte M, Stroffolini T, Vian A et al.. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.  Cancer. 1999;  85 2132-2137
    CrossrefPubMedGoogle Scholar
  • 24 Ikeda K, Arase Y, Kobayashi M et al.. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients.  Intervirology. 2003;  46 96-104
    CrossrefPubMedGoogle Scholar
  • 25 Mahmood S, Niiyama G, Kamei A et al.. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.  Liver Int. 2005;  25 220-225
    CrossrefPubMedGoogle Scholar
  • 26 Di Marco V, Lo Iacono O, Camma C et al.. The long-term course of chronic hepatitis B.  Hepatology. 1999;  30 257-264
    CrossrefPubMedGoogle Scholar
  • 27 Hui A Y, Chan H L, Leung N W et al.. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation.  J Clin Gastroenterol. 2002;  34 569-572
    CrossrefPubMedGoogle Scholar
  • 28 Fattovich G, Giustina G, Sanchez-Tapias J et al.. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).  Am J Gastroenterol. 1998;  93 896-900
    CrossrefPubMedGoogle Scholar
  • 29 Liaw Y F. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.  Semin Liver Dis. 2005;  25(suppl 1) 40-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Niederau C, Heintges T, Lange S et al.. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med. 1996;  334 1422-1427
    CrossrefPubMedGoogle Scholar
  • 31 Lau D T, Everhart J, Kleiner D E et al.. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.  Gastroenterology. 1997;  113 1660-1667
    PubMedGoogle Scholar
  • 32 van Zonneveld M, Honkoop P, Hansen B E et al.. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.  Hepatology. 2004;  39 804-810
    CrossrefPubMedGoogle Scholar
  • 33 Lin S M, Tai D I, Chien R N et al.. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.  J Viral Hepat. 2004;  11 349-357
    CrossrefPubMedGoogle Scholar
  • 34 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol. 2001;  34 306-313
    CrossrefPubMedGoogle Scholar
  • 35 Brunetto M R, Oliveri F, Coco B et al.. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.  J Hepatol. 2002;  36 263-270
    PubMedGoogle Scholar
  • 36 Oon C J. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions.  Cancer Chemother Pharmacol. 1992;  31(suppl) S137-S142
    CrossrefPubMedGoogle Scholar
  • 37 Mazzella G, Accogli E, Sottili S et al.. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.  J Hepatol. 1996;  24 141-147
    CrossrefPubMedGoogle Scholar
  • 38 Benvegnu L, Chemello L, Noventa F et al.. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis.  Cancer. 1998;  83 901-909
    CrossrefPubMedGoogle Scholar
  • 39 International Interferon-α Hepatocellular Carcinoma Study Group . Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study.  Lancet. 1998;  351 1535-1539
    CrossrefPubMedGoogle Scholar
  • 40 Cooksley W G, Piratvisuth T, Lee S D et al.. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.  J Viral Hepat. 2003;  10 298-305
    CrossrefPubMedGoogle Scholar
  • 41 Marcellin P, Lau G K, Bonino F et al.. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2004;  351 1206-1217
    CrossrefPubMedGoogle Scholar
  • 42 Lau G K, Piratvisuth T, Luo K X et al.. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2005;  352 2682-2695
    CrossrefPubMedGoogle Scholar
  • 43 Janssen H L, van Zonneveld M, Senturk H et al.. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.  Lancet. 2005;  365 123-129
    CrossrefPubMedGoogle Scholar
  • 44 Dienstag J, Goldin R, Heathcote E J et al.. Histological outcome during long-term lamivusine therapy.  Gastroenterology. 2003;  124 105-117
    CrossrefPubMedGoogle Scholar
  • 45 Di Marco V, Marzano A, Lampertico P et al.. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.  Hepatology. 2004;  40 883-891
    CrossrefPubMedGoogle Scholar
  • 46 Papatheodoridis G V, Dimou E, Dimakopoulos K et al.. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.  Hepatology. 2005;  42 121-129
    CrossrefPubMedGoogle Scholar
  • 47 Hadziyannis S J, Tassopoulos N C, Heathcote E J et al.. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.  N Engl J Med. 2005;  352 2673-2681
    CrossrefPubMedGoogle Scholar
  • 48 Chien R N, Lin C H, Liaw Y F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.  J Hepatol. 2003;  38 322-327
    CrossrefPubMedGoogle Scholar
  • 49 Hoofnagle J H, Di Bisceglie A M, Waggoner J G, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.  Gastroenterology. 1993;  104 1116-1121
    PubMedGoogle Scholar
  • 50 Perrillo R, Tamburro C, Regenstein F et al.. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.  Gastroenterology. 1995;  109 908-916
    PubMedGoogle Scholar
  • 51 Villeneuve J P, Condreay L D, Willems B et al.. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.  Hepatology. 2000;  31 207-210
    CrossrefPubMedGoogle Scholar
  • 52 Kapoor D, Guptan R C, Wakil S M et al.. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.  J Hepatol. 2000;  33 308-312
    CrossrefPubMedGoogle Scholar
  • 53 Yao F Y, Bass N M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.  J Hepatol. 2000;  33 301-307
    CrossrefPubMedGoogle Scholar
  • 54 Yao F Y, Terrault N A, Freise C, Maslow L, Bass N M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.  Hepatology. 2001;  34 411-416
    CrossrefPubMedGoogle Scholar
  • 55 Perrillo R P, Wright T, Rakela J et al.. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.  Hepatology. 2001;  33 424-432
    CrossrefPubMedGoogle Scholar
  • 56 Andreone P, Biselli M, Gramenzi A et al.. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation.  Transplantation. 2002;  74 1119-1124
    PubMedGoogle Scholar
  • 57 Fontana R J, Keeffe E B, Carey W et al.. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.  Liver Transpl. 2002;  8 433-439
    CrossrefPubMedGoogle Scholar
  • 58 Fontana R J, Hann H W, Perrillo R P et al.. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.  Gastroenterology. 2002;  123 719-727
    CrossrefPubMedGoogle Scholar
  • 59 Hann H W, Fontana R J, Wright T et al.. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.  Liver Transpl. 2003;  9 49-56
    CrossrefPubMedGoogle Scholar
  • 60 Manolakopoulos S, Karatapanis S, Elefsiniotis J et al.. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.  Am J Gastroenterol. 2004;  99 57-63
    CrossrefPubMedGoogle Scholar
  • 61 Bae S H, Yoon S K, Choi J Y et al.. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.  J Gastroenterol Hepatol. 2005;  20 1527-1532
    CrossrefPubMedGoogle Scholar
  • 62 Schiff E R, Lai C L, Hadziyannis S et al.. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.  Hepatology. 2003;  38 1419-1427
    PubMedGoogle Scholar
  • 63 Kim K M, Choi W B, Lim Y S et al.. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.  J Korean Med Sci. 2005;  20 821-828
    PubMedGoogle Scholar
  • 64 Liaw Y F, Lee C M, Chien R N, Yeh C T. Switching to adefovir monotherapy after emergence of lamivudine resistant mutations in patients with liver cirrhosis.  J Viral Hepat. 2006;  13 250-255
    CrossrefPubMedGoogle Scholar

 Professor
Yun-Fan LiawM.D. 

Liver Research Unit, Chang Gung Memorial Hospital

199, Tung Hwa North Road, Taipei 105, Taiwan

      >